Trial Profile

A PHASE 1B STUDY OF PF-05082566 IN COMBINATION WITH MOGAMULIZUMAB (KW-0761) IN PATIENTS WITH ADVANCED SOLID TUMORS

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 22 Apr 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Mogamulizumab (Primary) ; Utomilumab (Primary)
Indications Bladder cancer; Colorectal cancer; Head and neck cancer; Non-small cell lung cancer; Ovarian cancer; Solid tumours; Squamous cell cancer
Focus Adverse reactions
Sponsors Pfizer

18 Mar 2022 Results from NCT01307267, NCT02179918 and NCT02444793 comparing the anti drug antibody of utomilumab and its impact on the PK, safety, and efficacy in patients with advanced cancer, presented at the 123rd Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
24 Apr 2018 Status changed from recruiting to discontinued due to marginal efficacy and change in sponsor prioritization. The combination had a manageable safety profile.
27 Oct 2017 Planned End Date changed from 1 Jan 2018 to 1 Oct 2017.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com